Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL), a biopharmaceutical company specializing in MASH therapeutics, has announced equity inducement awards for 76 new non-executive employees under its 2025 Inducement Plan. The awards, approved by the company's Compensation Committee under Nasdaq Rule 5635(c)(4), include:

The grants consist of options to purchase 2,015 shares of common stock at $425.60 per share and 31,821 time-based restricted stock units. Options vest 25% after one year, followed by 6.25% quarterly thereafter. Restricted stock units vest in four equal annual installments, subject to continued employment.

Positive

• Expansion of workforce with 76 new non-executive employees indicating company growth

Negative

• None.

CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 15, 2025 to 76 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 2,015 shares of Madrigal’s common stock, and in the aggregate 31,821 time-based restricted stock units. Options have an exercise price of $425.60 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact

Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal Pharmaceuticals (MDGL) grant to new employees in September 2025?

Madrigal granted options to purchase 2,015 shares at $425.60 per share and 31,821 restricted stock units to 76 new non-executive employees.

What is the vesting schedule for MDGL's September 2025 employee stock options?

The options vest 25% after the first year, followed by 6.25% quarterly thereafter, subject to continued employment.

How do the restricted stock units (RSUs) vest in Madrigal's September 2025 inducement awards?

The RSUs vest in four equal annual installments over four years, subject to continued employment.

How many new employees received inducement awards from Madrigal Pharmaceuticals in September 2025?

76 new non-executive employees received equity inducement awards under Madrigal's 2025 Inducement Plan.